To validate whether ZEB1 promotes chemoresistance in vivo, we treated tumour-bearing animals grafted with either shZEB1 or shGFP cells with one cycle (five doses) of clinically relevant TMZ concentrations (20 mg/kg (Zhou et al, 2007)). This evidence concerns the gene ZEB1 and neoplasm.